Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

cts receive Traficet-EN. Patients who achieve a pre-specified reduction in disease severity are re-randomized to active drug or placebo for an additional 36-week 'Maintenance Period', thereby permitting an evaluation of the drug's ability to maintain a treatment response.

Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system.

About Traficet-EN(TM) (CCX282-B)

Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 clinical trial in Crohn's disease, Traficet-EN is being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role. ChemoCentryx has completed five Phase I clinical trials and one four-week Phase II Crohn's disease trial of Traficet-EN, demonstrating that the product candidate is well-tolerated and appropriate for once-daily oral dosing. Traficet-EN may offer advantages
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015  New guidelines released today by ... give hope for better outcomes to the hundreds ... ischemic stroke each year. Stryker,s Trevo ® ... in the clinical trials that provided data for ... strongly recommend endovascular therapy with stent retrievers for ...
(Date:6/29/2015)... PAUL, Minn. , June 29, 2015 ... manufacturer of devices that use neuroblocking technology to treat ... that it has commenced an underwritten public offering of ... common stock, Series A warrants to purchase common stock ... whose purchase of units in the offering would result ...
(Date:6/29/2015)... Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a pharmaceutical ... of prescription ophthalmic pharmaceuticals, today announced that Rick ... will present at the 2015 Cantor Fitzgerald Inaugural Healthcare ... at Le Parker Meridien Hotel in New ... webcast live and will be available for access, along ...
Breaking Medicine Technology:New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
... , ATLANTA , Feb. 8 ... an Atlanta -based, biopharmaceutical company developing human vaccines for ... agents, today provided an update on its vaccine trials progress. ... rate, 60,000 new infections annually, and that,s just in ...
... , PORTLAND, Ore. , Feb. 8 ... use of localized content by sales teams. Together, the companies ... translated content to reach the hands of global sales professionals ... sales cycle. This combination gives the sales person the right ...
Cached Medicine Technology:GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA 2GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA 3GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA 4GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA 5GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA 6Prolifiq and viaLanguage Announce Partnership: Accelerate the Use of Localized Content by Sales Teams 2Prolifiq and viaLanguage Announce Partnership: Accelerate the Use of Localized Content by Sales Teams 3
(Date:6/30/2015)... ... , ... AvePoint, the established leader in enabling enterprise collaboration across ... AvePoint Watermark, AvePoint MyWorld, and AvePoint PDF Aggregator – for ... streamline everyday business operations and take advantage of the latest Microsoft technologies to enhance ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... 28-31, 2015 at Disney’s Coronado Springs Resort in Lake Buena Vista, Florida, and ... year, this premiere event for psychiatric-mental health nursing draws more than 1,500 health ...
(Date:6/30/2015)... ... ... This Fourth of July, Peacock Alley celebrates the American ideals that ... commitment to quality, honesty and love of friends and family. These are the values ... of quilts, Peacock Alley was fully realized and grown while raising her family. Today, ...
(Date:6/29/2015)... St. Petersburg, FL (PRWEB) , ... June 30, 2015 , ... ... with a special 50% Off offer. The oil, ideal for natural skincare and ... a natural and easy way is something most people desire, and Oil Pulling can ...
(Date:6/29/2015)... ... 30, 2015 , ... With thousands of children in Utah Valley diagnosed on ... support center, planned at Utah Valley University, in Orem, Utah. The University has ... the building in which it will be housed. , Utah Valley has the highest ...
Breaking Medicine News(10 mins):Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 2Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 4Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3
... studies to test its treatment against Herpes Keratitis, when the ... that the treatment did not prove successful when tested on ... the efficacy of QR-435 in quelling the virus showed that ... period required to kill the virus. But during many other ...
... cough up 61 million U.S. dollars to take the anti-bird flu ... in the budget for 2007 as// compared to the spending allocated ... National Committee for bird flu control, Bayu Krishnamurthi, the added spending ... anti bird flu drive. So far there have been 74 human ...
... done it. Eating fish while expecting has been considered healthy, ... ,A study, to be published in the British Journal ... women into their 24 Th week. Amounts of mercury in ... the fetuses were noted to be way ahead of the ...
... while cholesterol-lowering drugs do increase the risk of painful ... rare//, according to Sonal Singh, M.D., from Wake Forest ... is a fairly common condition and cholesterol-lowering drugs have ... of people around the world take these drugs, our ...
... not individuals – are critical to the prevention of ... health, safety//, and welfare of patients, according to an ... today’s issue of the New England Journal of Medicine. ... of devices and catheters to deliver intravenous fluids and ...
... says, New Yorkers are less likely to die of a ... has the second-highest death rate from coronary// heart disease. ... 2003, only 35 of every 100,000 New York residents died ... heart disease. ,Oklahoma leads with 228. Hawaii had ...
Cached Medicine News:Health News:Nothing Fishy About This 2Health News:Risk of Acute Pancreatitis Low With Statins 2Health News:Medical Teams Are Key to Patient Safety 2
Inquire...
... Tips offer a safe alternative to using ... for applications such as PCR(a), pipetting radioactive ... Tips are excellent for tissue culture, gel ... Tips prevent aerosol contaminants and liquids from ...
... Eliminate aerosol contamination, ... reactions in PCR. Hydrophobic, ... Only air can pass ... tips, in contrast to ...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
Medicine Products: